Perspective Therapeutics (NYSE:CATX) Now Covered by Scotiabank

Scotiabank started coverage on shares of Perspective Therapeutics (NYSE:CATX) in a report issued on Friday morning, MarketBeat Ratings reports. The firm issued a sector outperform rating and a $15.00 target price on the stock.

A number of other research analysts have also commented on the stock. Royal Bank of Canada restated an “outperform” rating and set a $16.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Friday, January 24th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday. Oppenheimer cut their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Finally, Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Perspective Therapeutics has a consensus rating of “Buy” and a consensus price target of $15.13.

Perspective Therapeutics Stock Performance

CATX opened at $2.61 on Friday. The company has a fifty day moving average price of $3.21 and a 200-day moving average price of $7.76. Perspective Therapeutics has a one year low of $2.32 and a one year high of $19.05.

Institutional Trading of Perspective Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd purchased a new stake in Perspective Therapeutics during the fourth quarter valued at about $33,000. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics during the fourth quarter valued at about $34,000. National Bank of Canada FI raised its stake in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after acquiring an additional 10,998 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after acquiring an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. bought a new position in shares of Perspective Therapeutics during the fourth quarter valued at about $51,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.